Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria.
The activity of atovaquone in patients with oligosymptomatic Plasmodium falciparum malaria was assessed in an open, non-comparative clinical study. The patients showed a good clinical response, but there was a high rate of recrudescence. The activity of atovaquone in combination with another antimalarial agent should be investigated.
Chiodini
P L
PL
Department of Clinical Parasitology, Hospital for Tropical Diseases, London.
Conlon
C P
CP
Hutchinson
D B
DB
Farquhar
J A
JA
Hall
A P
AP
Peto
T E
TE
Birley
H
H
Warrell
D A
DA
D000328:Adult; D000962:Antimalarials / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D053626:Atovaquone; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D006801:Humans; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
D000962:Antimalarials; D009285:Naphthoquinones; D053626:Atovaquone